Journal of Clinical Oncology, Vol 19, Issue 3
(February), 2001: 602-611
© 2001 American Society for Clinical Oncology
Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial
By the French Adjuvant Study Group
Collaborators and their affiliations are listed in Appendix.
Address reprint requests to Jacques Bonneterre, MD, PhD, Département de Sénologie et Cancérologie Gynécologique, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59020 Lille, Cedex, France; email: j-bonneterre{at}o-lambret.fr
PURPOSE: To determine the influence of the epirubicin dose in operable node-positive breast cancer patients with factors of poor prognosis.
PATIENTS AND METHODS: Between April 1990 and July 1993, 565 operable breast cancer patients with either more than three positive nodes or between one and three positive nodes with Scarff Bloom Richardson grade  2 and hormone receptor negativity were randomized after surgery to receive either fluorouracil 500 mg/m2, epirubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 every 21 days for six cycles (FEC 50) or the same regimen except with epirubicin dose of 100 mg/m2 (FEC 100). Postmenopausal patients received tamoxifen 30 mg/d for 3 years at the beginning of chemotherapy. Radiotherapy was delivered at the end of chemotherapy in both groups.
RESULTS: The median follow-up was 67 months. The 5-year disease-free survival (DFS) was 54.8% with FEC 50 and 66.3% with FEC 100 (P = .03). The 5-year overall survival (OS) was 65.3% and 77.4%, respectively (P = .007). The mean relative dose-intensity was similar in the two groups (90.3% and 86.1%, respectively). Neutropenia and anemia were significantly more frequent in FEC 100 (P < 10-3), as were nausea-vomiting (P = .008) and stomatitis and alopecia (P < 10-3). Nine cases of grade 3 infection occurred only with FEC 100, and no toxic deaths occurred. Three cases of acute cardiac toxicity were observed (FEC50 = 1, FEC100 = 2) and 10 patients (FEC50 = 6, FEC100 = 4) presented delayed cardiac dysfunctions. Two cases of secondary leukemia were observed (acute lymphatic leukemia with FEC 50 and acute myelogenous leukemia with FEC 100).
CONCLUSION: After 5 years of follow-up, the increased epirubicin dose led to a significant benefit in terms of DFS and OS, with a high survival rate among patients with poor-prognosis breast cancer.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
T. ISHIKAWA, S. SHIMIZU, K. KATAYAMA, T. CHISHIMA, Y. HAMAGUCHI, T. DOI, M. TANABE, A. KASAHARA, N. YAMAGUCHI, K. NARUI, et al.
Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan
Anticancer Res,
May 1, 2009;
29(5):
1515 - 1520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Morris, H. L. McArthur, C. T. Dang, and C. A. Hudis
Selection of Appropriate Patients for Anthracycline Therapy
ASCO Educational Book,
January 1, 2009;
2009(1):
11 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Del Mastro, B. Dozin, E. Aitini, T. Catzeddu, E. Baldini, A. Contu, A. Durando, S. Danese, G. Cavazzini, G. Canavese, et al.
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group
Ann. Onc.,
February 1, 2008;
19(2):
299 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Findlay, K. Tonkin, M. Crump, B. Norris, M. Trudeau, M. Blackstein, M. Burnell, J. Skillings, D. Bowman, D. Walde, et al.
A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes
Ann. Onc.,
October 1, 2007;
18(10):
1646 - 1651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Conforti, T Boulet, G Tomasic, E Taranchon, R Arriagada, M Spielmann, M Ducourtieux, J. Soria, T Tursz, S Delaloge, et al.
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials
Ann. Onc.,
September 1, 2007;
18(9):
1477 - 1483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Lonning, S Knappskog, V Staalesen, R Chrisanthar, and J. Lillehaug
Breast cancer prognostication and prediction in the postgenomic era
Ann. Onc.,
August 1, 2007;
18(8):
1293 - 1306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Ann. Onc.,
July 1, 2007;
18(7):
1133 - 1144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N Wilking, E Lidbrink, T Wiklund, B Erikstein, H Lindman, P Malmstrom, P Kellokumpu-Lehtinen, N-O Bengtsson, G Soderlund, G Anker, et al.
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Ann. Onc.,
April 1, 2007;
18(4):
694 - 700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Sanna, K Lorizzo, N Rotmensz, V Bagnardi, S Cinieri, M Colleoni, F Nole, and A Goldhirsch
Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors
Ann. Onc.,
February 1, 2007;
18(2):
288 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Poole, H. M. Earl, L. Hiller, J. A. Dunn, S. Bathers, R. J. Grieve, D. A. Spooner, R. K. Agrawal, I. N. Fernando, A. M. Brunt, et al.
Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer
N. Engl. J. Med.,
November 2, 2006;
355(18):
1851 - 1862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lohrisch, C. Paltiel, K. Gelmon, C. Speers, S. Taylor, J. Barnett, and I. A. Olivotto
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
J. Clin. Oncol.,
October 20, 2006;
24(30):
4888 - 4894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Papaldo, G. Ferretti, S. Di Cosimo, D. Giannarelli, P. Marolla, M. Lopez, E. Cortesi, M. Antimi, E. Terzoli, P. Carlini, et al.
Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
J. Clin. Oncol.,
July 1, 2006;
24(19):
3048 - 3055.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Oncologist,
February 1, 2006;
11(2):
111 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Namer, P. Fargeot, H. Roche, M. Campone, P. Kerbrat, P. Romestaing, A. Monnier, E. Luporsi, P. Montcuquet, J. Bonneterre, et al.
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials
Ann. Onc.,
January 1, 2006;
17(1):
65 - 73.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Venturini, L. Del Mastro, E. Aitini, E. Baldini, C. Caroti, A. Contu, F. Testore, F. Brema, P. Pronzato, G. Cavazzini, et al.
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
J Natl Cancer Inst,
December 7, 2005;
97(23):
1724 - 1733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Hutchins, S. J. Green, P. M. Ravdin, D. Lew, S. Martino, M. Abeloff, A. P. Lyss, C. Allred, S. E. Rivkin, and C. K. Osborne
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
J. Clin. Oncol.,
November 20, 2005;
23(33):
8313 - 8321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cianfrocca and W. J. Gradishar
Controversies in the Therapy of Early Stage Breast Cancer
Oncologist,
November 1, 2005;
10(10):
766 - 779.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gluck
Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin
Oncologist,
November 1, 2005;
10(10):
780 - 791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Papaldo, M. Lopez, P. Marolla, E. Cortesi, M. Antimi, E. Terzoli, P. Vici, C. Barone, G. Ferretti, S. Di Cosimo, et al.
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide
J. Clin. Oncol.,
October 1, 2005;
23(28):
6908 - 6918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-C. Lin, S.-C. Chen, H.-K. Chang, S. Hsueh, C.-S. Tsai, Y.-F. Lo, T.-L. Hwang, and M.-F. Chen
Identifying Good Prognosis Group of Breast Cancer Patients with 1-3 Positive Axillary Nodes for Adjuvant Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) Chemotherapy
Jpn. J. Clin. Oncol.,
September 1, 2005;
35(9):
514 - 519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Stewart, A. H. G. Paterson, J. D. Ruether, J. Russell, P. Craighead, M. Smylie, and J. Mackey
High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study
Ann. Onc.,
September 1, 2005;
16(9):
1463 - 1468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chua, I. E. Smith, R. P. A'Hern, G. A. Coombes, T. F. Hickish, A. C. Robinson, R. W. Laing, M. E. R. O'Brien, S. R. Ebbs, A. Hong, et al.
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)
Ann. Onc.,
September 1, 2005;
16(9):
1435 - 1441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Howell and A. M Wardley
Overview of the impact of conventional systemic therapies on breast cancer
Endocr. Relat. Cancer,
July 1, 2005;
12(Supplement_1):
S9 - S16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Praga, J. Bergh, J. Bliss, J. Bonneterre, B. Cesana, R. C. Coombes, P. Fargeot, A. Folin, P. Fumoleau, R. Giuliani, et al.
Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide
J. Clin. Oncol.,
June 20, 2005;
23(18):
4179 - 4191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bonneterre, C. Bercez, M.-E. Bonneterre, X. Lenne, and B. Dervaux
Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study)
Ann. Onc.,
June 1, 2005;
16(6):
915 - 922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. G. C. Brain, T. Bachelot, D. Serin, S. Kirscher, Y. Graic, J.-C. Eymard, J.-M. Extra, M. Combe, E. Fourme, C. Nogues, et al.
Life-Threatening Sepsis Associated With Adjuvant Doxorubicin Plus Docetaxel for Intermediate-Risk Breast Cancer
JAMA,
May 18, 2005;
293(19):
2367 - 2371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Andre, A. Khalil, K. Slimane, C. Massard, M. C. Mathieu, S. Vignot, H. Assi, S. Delaloge, and M. Spielmann
Mitotic Index and Benefit of Adjuvant Anthracycline-Based Chemotherapy in Patients With Early Breast Cancer
J. Clin. Oncol.,
May 1, 2005;
23(13):
2996 - 3000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bonneterre, H. Roche, P. Kerbrat, A. Bremond, P. Fumoleau, M. Namer, M.-J. Goudier, S. Schraub, P. Fargeot, and I. Chapelle-Marcillac
Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial
J. Clin. Oncol.,
April 20, 2005;
23(12):
2686 - 2693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hamilton and G. Hortobagyi
Chemotherapy: What Progress in the Last 5 Years?
J. Clin. Oncol.,
March 10, 2005;
23(8):
1760 - 1775.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sandstrom, H. Lindman, P. Nygren, E. Lidbrink, J. Bergh, and M.O. Karlsson
Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients
J. Clin. Oncol.,
January 20, 2005;
23(3):
413 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Dang, G. M. D'Andrea, M. E. Moynahan, M. N. Dickler, A. D. Seidman, M. Fornier, M. E. Robson, M. Theodoulou, D. Lake, V. E. Currie, et al.
Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer
Clin. Cancer Res.,
September 1, 2004;
10(17):
5754 - 5761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bonneterre, H. Roche, P. Kerbrat, P. Fumoleau, M.-J. Goudier, P. Fargeot, P. Montcuquet, P. Clavere, J.-C. Barats, A. Monnier, et al.
Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group
J. Clin. Oncol.,
August 1, 2004;
22(15):
3070 - 3079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Shenkier, L. Weir, M. Levine, I. Olivotto, T. Whelan, and L. Reyno
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer
Can. Med. Assoc. J.,
March 16, 2004;
170(6):
983 - 994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Brandberg, H. Michelson, B. Nilsson, C. Bolund, B. Erikstein, P. Hietanen, S. Kaasa, J. Nilsson, T. Wiklund, N. Wilking, et al.
Quality of Life in Women With Breast Cancer During the First Year After Random Assignment to Adjuvant Treatment With Marrow-Supported High-Dose Chemotherapy With Cyclophosphamide, Thiotepa, and Carboplatin or Tailored Therapy With Fluorouracil, Epirubicin, and Cyclophosphamide: Scandinavian Breast Group Study 9401
J. Clin. Oncol.,
October 1, 2003;
21(19):
3659 - 3664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Papaldo, M. Lopez, E. Cortesi, E. Cammilluzzi, M. Antimi, E. Terzoli, G. Lepidini, P. Vici, C. Barone, G. Ferretti, et al.
Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide
J. Clin. Oncol.,
September 15, 2003;
21(18):
3462 - 3468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Crump, D. Tu, L. Shepherd, M. Levine, V. Bramwell, and K. Pritchard
Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol.,
August 15, 2003;
21(16):
3066 - 3071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Campos
Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer
Oncologist,
August 1, 2003;
8(90002):
10 - 16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Arriagada and J. Gutierrez
Anthracyclines: is more, better and/or more dangerous?
Ann. Onc.,
May 1, 2003;
14(5):
663 - 665.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bernard-Marty, M. Mano, M. Paesmans, C. Accettura, R. Munoz-Bermeo, T. Richard, K. Kleiber, F. Cardoso, J. P. Lobelle, D. Larsimont, et al.
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients
Ann. Onc.,
May 1, 2003;
14(5):
693 - 698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fumoleau, J. Bonneterre, and E. Luporsi
Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients: Which is the Reference Today?
J. Clin. Oncol.,
March 15, 2003;
21(6):
1190 - 1191.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-M. A. Nabholtz
In Reply:
J. Clin. Oncol.,
March 15, 2003;
21(6):
1191 - 1192.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fumoleau, P. Kerbrat, P. Romestaing, P. Fargeot, A. Bremond, M. Namer, S. Schraub, M.-J. Goudier, J. Mihura, A. Monnier, et al.
Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial
J. Clin. Oncol.,
January 15, 2003;
21(2):
298 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Pritchard
Adjuvant Therapy for Premenopausal Women With Breast Cancer: Is It Time for Another Paradigm Shift?
J. Clin. Oncol.,
December 15, 2002;
20(24):
4611 - 4614.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Heidemann, H. Stoeger, R. Souchon, W.-D. Hirschmann, H. Bodenstein, C. Oberhoff, J. T. Fischer, M. Schulze, M. Clemens, R. Andreesen, et al.
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial
Ann. Onc.,
November 1, 2002;
13(11):
1717 - 1729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Arriagada, M. Spielmann, S. Koscielny, T. Le Chevalier, T. Delozier, M. Ducourtieux, T. Tursz, and C. Hill
Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen
Ann. Onc.,
September 1, 2002;
13(9):
1378 - 1386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Di Leo and M. Buyse
Equivalence Between Ovarian Suppression and Chemotherapy in the Adjuvant Treatment of Endocrine-Responsive Breast Cancer
J. Clin. Oncol.,
April 1, 2002;
20(7):
1954 - 1955.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, and H.-J. Senn
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
J. Clin. Oncol.,
September 15, 2001;
19(18):
3817 - 3827.
[Full Text]
[PDF]
|
|
|
|
